EN DE
Watch VISTA PHARMACEUTICALS LTD. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

VISTA PHARMACEUTICALS LTD. (VISTAPH) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of VISTA PHARMACEUTICALS LTD. stock ₹5.65, price ₹6.15, that is 8.1% below the price, quality 24 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE427C01021

VP VISTA PHARMACEUTICALS LTD. logo Thin data Nov 17, 2026

VISTA PHARMACEUTICALS LTD.

VISTAPH · BSE

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Fair value ₹5.65 · Fairly valued 
Mixed Growth (revenue 5y +33.6 %/yr in INR) 
Quality 24/100 
Falling price (downtrend) 
Loss-making · -89.2% net margin (TTM) 
Negative free cash flow 
Trails peers (3/9) 
Narrow moat 10/100 · thin data
Thin data 
Estimate⚠ Thinly traded⚠ Small free float
Watch VISTA PHARMACEUTICALS LTD. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹19.32 ₹5.36 Fair Value ₹5.65 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range ₹5.36 – ₹19.32 · fair‑value band ₹4.24 – ₹7.07 · the ₹6.15 price screens above the ₹5.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow VISTA PHARMACEUTICALS in your weekly email

Every Wednesday you see whether VISTA PHARMACEUTICALS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vista Pharmaceuticals Limited manufactures and sells pharmaceutical, medical, and veterinary preparations in India, the United States, and internationally. It offers over the counter and prescription generic drugs consisting of tablets, capsules, and liquids covering various therapeutic categories.

Show moreShow less

Vista Pharmaceuticals Limited was incorporated in 1991 and is based in Hyderabad, India.

Stock analysis

VISTA PHARMACEUTICALS LTD. (VISTAPH) currently trades at ₹6.15, while our estimate is ₹5.65, so the stock looks roughly fairly valued today (gap 8.8%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₹4.24 (bear) to ₹7.07 (bull), the price of ₹6.15 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

VISTA PHARMACEUTICALS LTD. reported revenue of ₹54.0M in FY2026 versus ₹3.9M in FY2022, a compound +92.3%/yr. Reported net income was −₹121M in FY2026.

Key figures

Market cap ₹379M (≈ $4.1M) Micro · P/S ratio 4.60 · EPS (TTM) ₹−1.92 · Return on equity −16.6% · Return on assets (EBIT) −10.5% (5-year average) · Operating margin −2,584% · Revenue (TTM) ₹86.3M · Revenue growth (YoY) −97.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −8%, VISTAPH screens cheaper than that median.

Fair Value

Bear ₹4.24 Fair Value ₹5.65 Bull ₹7.07
Price ₹6.15 · Downside -8.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 24/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 3
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 47
Debt, balance sheet and risk of trouble
Investment 77
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−46.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+75.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.6%
Start year 2021 (pandemic). Over 10 years: −9.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−194.0% (2021) → −284.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch VISTAPH, get fair value alerts →

Compare VISTA PHARMACEUTICALS LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside −8.1% · Above median
Profitability
Return on assets −21.9% · Bottom 25%
Net margin (12 months) −89.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −97.4% · Bottom 25%
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.04× · Cheaper than median
P/S (12 months) 4.39× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)23 · sector 20
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)0 · sector 26
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $85.57 $113.53 +33% vs VISTAPH
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs VISTAPH
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs VISTAPH
Haleon plc HLN $9.08 $8.47 −7% vs VISTAPH
Merck KGaA MRK €148.40 €108.83 −27% vs VISTAPH
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs VISTAPH
Takeda Pharmaceutical Company TAK $21.27 $11.23 −47% vs VISTAPH
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs VISTAPH
Teva Pharmaceutical Industries Limited TEVA $42.23 $20.74 −51% vs VISTAPH
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs VISTAPH

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

VISTA PHARMACEUTICALS LTD.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "VISTA PHARMACEUTICALS LTD. Fair Value". https://www.fairvalue-calculator.com/stock/VISTAPH

Frequently asked questions

Is VISTA PHARMACEUTICALS LTD. (VISTAPH) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is ₹5.65 versus a price of ₹6.15, about 8% lower (fairly valued).
What is the fair value of VISTAPH?
Our estimate for VISTA PHARMACEUTICALS LTD. is ₹5.65 (as of Nov 17, 2026), built from audited fundamentals. The current price: ₹6.15.
What is the quality score of VISTAPH?
VISTA PHARMACEUTICALS LTD. has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for VISTA PHARMACEUTICALS LTD. (VISTAPH)?
We do not set a price target; the yardstick is our estimate of ₹5.65 (as of Nov 17, 2026). Cautious scenario ₹4.24, optimistic scenario ₹7.07. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the VISTA PHARMACEUTICALS LTD. stock forecast for 2026?
Our estimate puts fair value at ₹5.65, about 8% lower versus a price of ₹6.15 (fairly valued). Cautious scenario ₹4.24, optimistic scenario ₹7.07. The calculation is refreshed regularly with new filings.
What is the revenue of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
VISTA PHARMACEUTICALS LTD. reported trailing-twelve-month revenue of about ₹86.3M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For VISTA PHARMACEUTICALS LTD. it is ₹5.65 per share (as of Nov 17, 2026), against a price of ₹6.15.
Is VISTA PHARMACEUTICALS LTD. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, VISTAPH trades above its calculated fair value: price ₹6.15, fair value ₹5.65, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VISTAPH?
No. The price is what the market pays today (₹6.15); the fair value is what the company's own numbers justify (₹5.65). For VISTA PHARMACEUTICALS LTD. the two are ₹0.5000 per share apart. That gap is exactly why we show both numbers side by side.
How much is VISTA PHARMACEUTICALS LTD. worth?
The market values VISTA PHARMACEUTICALS LTD. at about ₹379M (market capitalisation, as of Nov 17, 2026). Per share that is ₹6.15; our models calculate a fair value of ₹5.65 per share.
What do the bullish and bearish scenarios say about VISTAPH?
Our models span a range for VISTA PHARMACEUTICALS LTD.: cautious scenario ₹4.24, base ₹5.65, optimistic ₹7.07 per share (as of Nov 17, 2026, price ₹6.15). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
Balance-sheet figures for VISTA PHARMACEUTICALS LTD. (as of Nov 17, 2026): return on equity −16.6%, debt of 0.05 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is VISTAPH from its 52-week high?
VISTA PHARMACEUTICALS LTD. trades at ₹6.15, about 33% below its 52-week high of ₹9.23 and 15% above the low of ₹5.36 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of ₹5.65 is for.
Which stocks are comparable to VISTA PHARMACEUTICALS LTD.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is VISTA PHARMACEUTICALS LTD. stock attractive at the current price?
The data as of Nov 17, 2026: price ₹6.15, calculated fair value ₹5.65 (−8%), Quality Score 24/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. VISTA PHARMACEUTICALS LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
The closing price on Nov 19, 2026 was ₹6.15. Our estimate is ₹5.65, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with VISTA PHARMACEUTICALS LTD. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of VISTA PHARMACEUTICALS LTD.

How large is the market capitalisation of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
The market capitalisation of VISTA PHARMACEUTICALS LTD. is ₹379M (≈ $4.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
The price-to-sales ratio of VISTA PHARMACEUTICALS LTD. is 4.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
Earnings per share at VISTA PHARMACEUTICALS LTD. are ₹−1.92. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
The return on equity (ROE) of VISTA PHARMACEUTICALS LTD. is −16.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
On an EBIT basis the return on assets of VISTA PHARMACEUTICALS LTD. is −10.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
The operating margin of VISTA PHARMACEUTICALS LTD. is −2,584% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at VISTA PHARMACEUTICALS LTD. (VISTAPH)?
Revenue at VISTA PHARMACEUTICALS LTD. is down 97.4% versus a year earlier (3y avg +75.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does VISTA PHARMACEUTICALS LTD. (VISTAPH) generate?
The free cash flow of VISTA PHARMACEUTICALS LTD. is −₹51.8M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does VISTA PHARMACEUTICALS LTD. (VISTAPH) carry?
The net debt of VISTA PHARMACEUTICALS LTD. is ₹98.8M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch VISTA PHARMACEUTICALS LTD. in the live analysis

One click puts VISTA PHARMACEUTICALS LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.